Brief: Oryzon To Sponsor Phelan-McDermid Syndrome Burden Of Illness Study
Sept 22 (Reuters) - Oryzon Genomics SA ORY.MC: TO SPONSOR FIRST PHELAN-MCDERMID SYNDROME (PMS) BURDEN OF ILLNESS STUDY STUDY LED BY CURESHANK Source text Further company coverage: ORY.MC (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on ORYZON Genomics SA
See all newsBrief: Oryzon Gets New Patent Grants For Vafidemstat In Four Countries
Brief: Oryzon Gets EMA Approval To Start Phase II Study Of Vafidemstat For PMS Treatment
Spanish stocks - Factors to watch on Aug 31
Brief: Oryzon Gets U.S. Patent Allowance For Iadademstat And Gilteritinib Drug Combo Application
Spanish stocks - Factors to watch on July 28